FDA warned C R Supplements that its mineral supplements were sold as unapproved new drugs and made without required quality controls.
What happened
FDA inspected the Kooskia, Idaho facility from December 6 to December 10, 2021, and reviewed the company's website and Facebook page in March and April 2022. The inspection found dietary supplement CGMP violations, including missing written specifications, quality control procedures, and incomplete master and batch manufacturing records. The website and Facebook page claimed the mineral products could treat or prevent disease, including flu, and FDA also cited labeling problems.
What FDA found
FDA found website and Facebook claims that the mineral products treat or prevent disease, such as flu, asthma, or infections, so FDA treats them as unapproved new drugs.
21 U.S.C. § 321(g)(1)(B), 321(p), 331(d), 355(a)The products lacked adequate directions for safe use by a layperson and are therefore misbranded.
21 U.S.C. § 352(f)(1); 21 CFR 201.5The firm had no written specifications for components, in-process steps, finished batches, packaging, or labels.
21 CFR 111.70(a)-(g)The firm did not establish or follow written quality control procedures or keep required quality control review records.
21 CFR 111.103, 111.140(b)(1)-(3)Master manufacturing records and batch production records were incomplete, not batch-specific, and missing required details about manufacturing, packaging, and quality control.
21 CFR 111.205(a), 111.210, 111.255(a), 111.260Silver and Magnesium labels had incorrect Supplement Facts format, missing child serving-size information, and 'Other ingredients' placed above the Supplement Facts panel.
21 U.S.C. § 343(q), 343(q)(5)(F); 21 CFR 101.9, 101.36, 101.4(g)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt of the specific steps taken to address the violations, with explanations and documentation, and to state any reason and timeframe if corrective actions cannot be completed within that time.
Who should pay attention
- dietary supplement firms making mineral or immune products
- contract manufacturers and labelers of liquid supplements
- companies making disease-treatment claims on websites or social media
This is a summary. Read the original letter on fda.gov.